Andrew Napoli, PhD

Bristol Myers Squibb
Pennsauken, NJ, United States

Andy Napoli, PhD is Vice President, Worldwide Medical, Immunology at Bristol Myers Squibb

Presentation(s):

• 2202: Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.